CRC

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Retrieved on: 
Wednesday, February 21, 2024

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy.
  • "TomaLab is the ideal partner to bring our pioneering product to Italy given its state-of-the-art facilities and commitment to innovative healthcare solutions," said Guido Baechler, CEO of Mainz Biomed.
  • "We are thrilled to collaborate with Mainz Biomed to incorporate ColoAlert® into our laboratory procedures," stated Dr. Riccardo Manca, CEO of TomaLab.
  • "This partnership underlines our dedication to embracing cutting-edge technologies that enhance patient care and outcomes."

Unleash live Joins AAM CRC in Advancing Australia's Aerospace and Aviation Industry

Retrieved on: 
Friday, March 8, 2024

Unleash live is excited to announce its participation in the Advanced Air Mobility Cooperative Research Centre (AAM CRC), a groundbreaking initiative aimed at transforming Australia's aerospace and aviation sector.

Key Points: 
  • Unleash live is excited to announce its participation in the Advanced Air Mobility Cooperative Research Centre (AAM CRC), a groundbreaking initiative aimed at transforming Australia's aerospace and aviation sector.
  • Through interdisciplinary collaboration, the CRC aims to propel Australia towards a clean, sustainable and globally competitive aerospace future.
  • As we move into Stage 2, Unleash live remains committed to supporting Australia's leadership in advanced autonomous air mobility.
  • Unleash live is proud to support this effort and together, let's lead the way in advanced air mobility."

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Retrieved on: 
Friday, March 1, 2024

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
  • The survey polled 1,000 American adults age 45-84, along with 351 physicians (250 primary care providers and 101 gastroenterologists).
  • In the United States, CRC screening guidelines recommend that all people of average risk begin screening starting at age 45.
  • Ultimately, 96% of all physicians surveyed would recommend an FDA-approved blood test to their patients for CRC screening.

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, February 27, 2024

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

Carbon TerraVault Provides 2023 Update

Retrieved on: 
Tuesday, February 27, 2024

Carbon TerraVault (CTV) today provided an update on its 2023 operations.

Key Points: 
  • Carbon TerraVault (CTV) today provided an update on its 2023 operations.
  • California Resources Corporation (NYSE: CRC) conducts its carbon management business through Carbon TerraVault which pursues carbon capture and sequestration projects that are directly sited or within close proximity to significant sources of carbon dioxide (CO2) emissions in California.
  • “During 2023, our team meaningfully advanced the expansion of our carbon management business by announcing new Carbon Dioxide Management Agreements (CDMAs)1, submitting new permits to the EPA and attracting new greenfield project capital to California,” said Francisco Leon, CRC’s President and Chief Executive Officer.
  • The CDMA provides a path for the parties to reach final definitive documents and final investment decision.

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Retrieved on: 
Monday, February 26, 2024

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.

Key Points: 
  • “These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.
  • JANX007 is in a Phase 1a clinical trial in subjects with advanced or metastatic prostate cancer (mCRPC).
  • As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a clinical trial.
  • Based on this safety profile, we are continuing in the dose escalation and optimization portion of the trial for JANX008.

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Retrieved on: 
Thursday, February 22, 2024

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
  • Development services and other revenue was $12.9 million for the fourth quarter of 2023, compared to $13.1 million for the corresponding prior year period.
  • Precision oncology gross margin was 60% in the fourth quarter of 2023, as compared to 62% in the prior year period.
  • Guardant Health will host a conference call to discuss the fourth quarter and full year 2023 financial results after market close on Thursday, February 22, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

Retrieved on: 
Tuesday, February 20, 2024

“The launch of NPX887, our second clinical program targeting the HHLA2/B7-H7 axis, marks an important step in broadening our therapeutic targeting of this novel pathway to reactivate the immune system to fight cancer,” commented Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics.

Key Points: 
  • “The launch of NPX887, our second clinical program targeting the HHLA2/B7-H7 axis, marks an important step in broadening our therapeutic targeting of this novel pathway to reactivate the immune system to fight cancer,” commented Leena Gandhi, MD, PhD, Chief Medical Officer of NextPoint Therapeutics.
  • “Together with NPX267, our first clinical program targeting the KIR3DL3 receptor for HHLA2, we are well-positioned to interrogate how best to exploit this pathway to effectively treat patients whose tumors express HHLA2 as an independent checkpoint of tumor-immune response from PD-L1.
  • Our goal for both clinical programs is to leverage HHLA2 as a biomarker to enable precision selection of patients most likely to benefit.
  • Both NPX267 and NPX887 have the potential for monotherapy benefit in selected patient populations.”

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...

Retrieved on: 
Tuesday, February 20, 2024

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.

Key Points: 
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.
  • “The acceptance of this filing for KRAZATI in combination with cetuximab is a positive step toward providing a potential new option for patients and their physicians.
  • The secondary endpoints for the pooled cohorts included duration of response, progression-free survival, overall survival and safety.
  • The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually.